Literature DB >> 24415532

EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.

Zhichao Zhou1, Ling Yu, Eugenie S Kleinerman.   

Abstract

BACKGROUND: RE1-silencing transcription factor (REST), a neuronal repressor gene, regulates neuronal stem cell differentiation. Ewing sarcoma may originate from neural crest cells. In the current study, the authors investigated whether REST plays a role in the growth of this tumor.
METHODS: REST expression was determined by Western blot analysis and reverse transcription-polymerase chain reaction in 3 human Ewing sarcoma cell lines and 7 patient tumor samples. The role of REST in tumor growth and tumor vascular morphology was determined using a Ewing sarcoma xenograft model. Immunofluorescence staining, Hypoxyprobe, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays were performed to investigate the impact of REST on pericyte marker expression, hypoxia, and apoptosis in vivo.
RESULTS: High levels of REST were expressed in all 3 human Ewing sarcoma cell lines and in 6 of the 7 patient tumor samples. Overexpression of EWS-FLI-1 in human mesenchymal stem cells and human neural progenitor cells was found to increase REST expression. Inhibition of EWS-FLI-1 using small interfering RNA decreased REST expression in human Ewing sarcoma cells. Inhibition of REST did not affect EWS-FLI-1, but significantly suppressed tumor growth in vivo, reduced the tumor vessel pericyte markers α- smooth muscle actin (SMA) and desmin, increased hypoxia and apoptosis in tumor tissues, and decreased the expression of delta-like ligand 4 (DLL4) and Hes1.
CONCLUSIONS: Inhibition of REST suppressed tumor growth, inhibited pericyte marker expression, and increased tumor hypoxia and apoptosis. Because tumor vessel function has been linked to tumor growth and metastases, REST may be a new therapeutic target in patients with Ewing sarcoma.
© 2013 American Cancer Society.

Entities:  

Keywords:  EWS-FLI-1; Ewing sarcoma; RE1-silencing transcription factor (REST); tumor growth; tumor vasculature

Mesh:

Substances:

Year:  2014        PMID: 24415532      PMCID: PMC3969734          DOI: 10.1002/cncr.28555

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

Review 1.  Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data.

Authors:  Steven G DuBois; Neyssa Marina; Julia Glade-Bender
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

2.  The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells.

Authors:  P Lawinger; R Venugopal; Z S Guo; A Immaneni; D Sengupta; W Lu; L Rastelli; A Marin Dias Carneiro; V Levin; G N Fuller; Y Echelard; S Majumder
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

3.  Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.

Authors:  James S Miser; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; Holcolmbe E Grier
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

4.  A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.

Authors:  Judy L Felgenhauer; Michael L Nieder; Mark D Krailo; Mark L Bernstein; David W Henry; David Malkin; Sylvain Baruchel; Paul J Chuba; Scott L Sailer; Ken Brown; Sarangarajan Ranganathan; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-10-12       Impact factor: 3.167

Review 5.  Biology of pediatric peripheral neuroectodermal tumors.

Authors:  C J Thiele
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

6.  Distinct RE-1 silencing transcription factor-containing complexes interact with different target genes.

Authors:  Nikolai D Belyaev; Ian C Wood; Alexander W Bruce; Miyoko Street; Jean-Baptiste Trinh; Noel J Buckley
Journal:  J Biol Chem       Date:  2003-10-15       Impact factor: 5.157

7.  Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing's sarcoma A673-xenograft growth and normalize tumor vascular architecture.

Authors:  Maximilian Ackermann; Brent A Morse; Vera Delventhal; Irvith M Carvajal; Moritz A Konerding
Journal:  Angiogenesis       Date:  2012-08-23       Impact factor: 9.596

8.  REST maintains self-renewal and pluripotency of embryonic stem cells.

Authors:  Sanjay K Singh; Mohamedi N Kagalwala; Jan Parker-Thornburg; Henry Adams; Sadhan Majumder
Journal:  Nature       Date:  2008-03-23       Impact factor: 49.962

9.  Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration.

Authors:  Jaime Morales-Arias; Paul A Meyers; Marcela F Bolontrade; Nidra Rodriguez; Zhichao Zhou; Krishna Reddy; Alexander J Chou; Nadezhda V Koshkina; Eugenie S Kleinerman
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

Review 10.  Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET.

Authors:  N Riggi; L Cironi; M-L Suvà; I Stamenkovic
Journal:  J Pathol       Date:  2007-09       Impact factor: 7.996

View more
  14 in total

Review 1.  Pericytes in sarcomas of bone.

Authors:  Le Chang; Vi Nguyen; Alan Nguyen; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-06-16       Impact factor: 3.064

2.  REST Final-Exon-Truncating Mutations Cause Hereditary Gingival Fibromatosis.

Authors:  Yavuz Bayram; Janson J White; Nursel Elcioglu; Megan T Cho; Neda Zadeh; Asuman Gedikbasi; Sukru Palanduz; Sukru Ozturk; Kivanc Cefle; Ozgur Kasapcopur; Zeynep Coban Akdemir; Davut Pehlivan; Amber Begtrup; Claudia M B Carvalho; Ingrid Sophie Paine; Ali Mentes; Kivanc Bektas-Kayhan; Ender Karaca; Shalini N Jhangiani; Donna M Muzny; Richard A Gibbs; James R Lupski
Journal:  Am J Hum Genet       Date:  2017-07-06       Impact factor: 11.025

Review 3.  Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.

Authors:  Balaji Ramachandran; Thangarajan Rajkumar; Gopal Gopisetty
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

4.  Detection of EWS/FLI-1 fusion in non-Ewing soft tissue tumors.

Authors:  I O Trancău; R Huică; M Surcel; A Munteanu; C Ursaciuc
Journal:  J Med Life       Date:  2014

Review 5.  Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes.

Authors:  Laurens G L Sand; Karoly Szuhai; Pancras C W Hogendoorn
Journal:  Int J Mol Sci       Date:  2015-07-16       Impact factor: 5.923

6.  REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature.

Authors:  Shavali Shaik; Bridget Kennis; Shinji Maegawa; Keri Schadler; Yang Yanwen; Keri Callegari; Rishi R Lulla; Stewart Goldman; Javad Nazarian; Veena Rajaram; Jason Fangusaro; Vidya Gopalakrishnan
Journal:  Oncotarget       Date:  2017-12-28

7.  WT1 regulates angiogenesis in Ewing Sarcoma.

Authors:  Varalakshmi Katuri; Stephanie Gerber; Xiaofei Qiu; Gregory McCarty; Seth D Goldstein; Hans Hammers; Elizabeth Montgomery; Allen R Chen; David M Loeb
Journal:  Oncotarget       Date:  2014-05-15

8.  Detection of EWS/FLI-1 fusion in non-Ewing soft tissue tumors.

Authors:  I O Trancău; R Huică; M Surcel; A Munteanu; C Ursaciuc
Journal:  J Med Life       Date:  2015 Jan-Mar

Review 9.  Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.

Authors:  Emily R Theisen; Kathleen I Pishas; Ranajeet S Saund; Stephen L Lessnick
Journal:  Oncotarget       Date:  2016-04-05

10.  Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis.

Authors:  Rubén Fernández-Rodríguez; Francisco Javier Rodríguez-Baena; Estefanía Martino-Echarri; Carlos Peris-Torres; María Del Carmen Plaza-Calonge; Juan Carlos Rodríguez-Manzaneque
Journal:  Oncotarget       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.